In November 2026

the original glp-1 drug just left its last major markets without ceremony

In November 2026, Byetta is essentially gone. The European Medicines Agency formally withdrew Byetta's marketing authorization effective January 1, 2026, at AstraZeneca's request, citing commercial reasons. The once-weekly version, Bydureon, was discontinued across the UK and US in 2024 and 2025 — also for commercial reasons, not because anything was wrong with the drug. These exits happened with minimal public notice, buried in pharmacy supply notifications and EMA press releases while the news cycle was occupied with Ozempic compounding lawsuits, Mounjaro cardiovascular outcome data, and retatrutide's phase 3 results. What none of the GLP-1 coverage adequately marked is the basic irony: the drug class making pharmaceutical history right now was proven viable by a peptide extracted from Gila monster saliva that just quietly left the building. Byetta launched GLP-1 medicine. Its successors do not appear to have noticed.

The lizard peptide

exenatide was copied from a gila monster — and that is not the unusual part

Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide found in the saliva of the Gila monster — Heloderma suspectum — a large, venomous lizard native to the southwestern United States and northern Mexico. Exendin-4 was identified in the early 1990s by John Eng, a researcher at the Veterans Affairs Medical Center in New York, who noticed it shared structural similarity with the incretin hormone GLP-1. What made it scientifically valuable was its resistance to DPP-4, the serum enzyme that degrades native GLP-1 within about two minutes. Exendin-4 lasts far longer, which makes its pharmacological effect measurably more sustained. The FDA approved exenatide in 2005 as the first GLP-1 receptor agonist for type 2 diabetes. The basic mechanism — bind the GLP-1 receptor, amplify glucose-dependent insulin secretion, slow gastric emptying, reduce appetite — is exactly what every GLP-1 drug on the market today does, including semaglutide and tirzepatide. [PubMed's exenatide literature](https://pubmed.ncbi.nlm.nih.gov/?term=exenatide) documents the clinical pharmacology from first-in-human studies through cardiovascular outcome trials. The molecule is a Gila monster peptide. That is not a marketing detail. That is the origin of the category.

What it delivered

byetta worked as advertised — the problem was what came next in the same class

When Byetta launched in 2005, the claims were narrow: a glucose-dependent insulin amplifier for type 2 diabetes that did not cause hypoglycemia the way sulfonylureas did, and that came with weight loss as a side effect rather than weight gain. The drug delivered within those constraints. HbA1c reductions ran approximately 0.5% to 1% in phase 3 trials, with 2 to 3 kg of weight loss over 30 weeks. Nausea was common early. The twice-daily injection schedule was inconvenient. The once-weekly Bydureon, approved in 2012, addressed the dosing problem but not the more fundamental one: newer molecules in the same class were simply better. Liraglutide's cardiovascular outcome data arrived with LEADER. Semaglutide's weight-loss magnitude in SUSTAIN and STEP rewrote what a GLP-1 agonist could plausibly do. By the time tirzepatide added GIP agonism, exenatide was not competing anymore — it had become the proof-of-concept that made the competition possible. The pitch for exenatide in 2026 is not that it failed. It is that it succeeded well enough for the class to leave it behind.

What the data says

the evidence record is real, narrow, and superseded — not disputed

Exenatide's clinical record is settled. The phase 3 trials that earned Byetta its 2005 approval documented significant HbA1c reduction versus placebo in patients with type 2 diabetes, with a glucose-dependent mechanism that avoided sulfonylurea-class hypoglycemia risk. [DailyMed's exenatide label](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=exenatide) tracks the approved formulations and their cardiovascular safety data, accumulated in post-approval studies through the drug's commercial years. [ClinicalTrials.gov's exenatide record](https://clinicaltrials.gov/search?term=exenatide) documents the full development program, including the head-to-head comparisons against later GLP-1 agents where the trajectory toward exit becomes legible: not a safety signal, not a failed outcome, but a consistent pattern of non-superiority against newer molecules. The EXSCEL cardiovascular outcome trial, completed in 2017, showed exenatide once-weekly was non-inferior to placebo on major adverse cardiovascular events — which is not the same result as semaglutide's SUSTAIN-6 or liraglutide's LEADER, both of which showed cardiovascular superiority. That gap, over ten years, is the gap between a drug that opened the category and the drugs that defined it.

Approved — PeptideFactCheck stance

the approved tier holds — the drug worked, and the category it proved is now everywhere

Exenatide holds PeptideFactCheck's Approved evidence tier. That classification reflects what it should: an FDA-approved drug with official labeling, human clinical trial evidence for its approved indication, and a full regulatory history. The Approved tier's tone says: regulatory certainty for labeled uses, not a blank check for every claim. In November 2026, the relevant question is not whether exenatide's evidence was real — it was — but what happens to the first entrant in a drug class when that class produces better molecules. The answer, apparently, is a quiet commercial exit across EU, UK, and US markets over two years, while the category continues its busiest regulatory and commercial period on record. That asymmetry does not make exenatide a footnote. It makes it the proof that the biology worked: a Gila monster peptide showed that activating the GLP-1 receptor in humans produced meaningful glucose control, real weight-change biology, and a safety profile acceptable enough to build a drug class on. [The FDA Orange Book](https://www.accessdata.fda.gov/scripts/cder/ob/) lists approved drug products by name — a database whose exenatide entries tell the story of a drug that earned approval and has now been superseded by its own successors. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.